Committees : RSFT DTC
You are here : Home > Committees : RSFT DTC
Committee Types
Please select an organisation name from the list below to view associated profiles and decisions.
Committee
- ASPH DTC
- East Surrey CCG Medicines Programme Board
- East Surrey MOG
- Epsom St Helier NDAIG
- ESCCG sub-committee of North Place Alliance Clinical Strategy Committee (formerly Clinical Executive
- Guildford and Waverley MOG
- Medicines Optimisation Operational Group (MOOG)
- Not Set
- NW Surrey Medicines Optimisation Group
- Primary Care Medicines Optimisation Clinical reference Group (PCMOCRG)
- RSFT DTC
- SASH DTG
- Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
- Surrey Downs CCG Prescribing Leads Meeting
- Surrey Downs MOG
- Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
- Surrey Heartlands Medicines Optimisation Board (MOB)
- Surrey Heartlands Medicines Safety Committee (MSC)
- Surrey Medicines Commissioners Group
- Surrey Priorities Committee
Trust
Profiles (0)
No records returned.
Committee Recommendations (11)
The RSFT Drugs and Therapeutics Committee will upload final minutes of the DTC to this page each month.
Please contact the DTC at rsch.dtc@nhs.net for previous minutes
Use in 5 years and up approved
Previously approved for adults. now approved for over 5 years
RSFT DTC October 2025
Approved for use in small bowel MRI to enable reproducible signal characteristics, luminal transit and distension without compromising patient acceptability, cost or safety
Joint formulary addition
Approved for adults only
Approved. ENT only
This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.
See “Formulary Status” to identify where this drug has been agreed for use.
Approved as Red for paediatric dermatology specialists only at RSFT DTC Jan 2024
This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.
See “Formulary Status” to identify where this drug has been agreed for use.